Abstract:Purpose: Metastatic colorectal cancer (mCRC) is the second leading cause of cancer death worldwide. Roughly 8% of mCRC tumors harbor a BRAF(V600E) mutation, associated with the worst prognosis and limited treatment options. Most CRC research and most clinical trials of targeted therapies have narrowly focused on targeting vertical mechanisms of MAPK re-activation (i.e., EGFR-MAPK), with incremental advances for patients. New approaches are needed to address how therapeutic resistance is mediated by coordinated upregulation of multiple signaling pathways. Methods and Recent Advances: Using an innovative high-throughput kinase-activity mapping (HT-KAM) platform and kinase network resource (PhosphoAtlas), we discovered that SRC kinases drive resistance to BRAF ± anti-EGFR therapy independently of ERK signaling by inducing adaptive transcriptional changes via beta-catenin. This compensatory activation of SRC was mediated by an autocrine PGE2-loop that could be blocked with COX2 inhibitors (COX2i). Using patient-derived xenograft (PDX) models established from pre-treatment biopsies in clinical trial participants, we showed that targeting COX2 in combination with standard of care (SOC) BRAFi + EGFRi is an effective drug repurposing strategy to stabilize tumor growth in vivo. New, Unpublished Findings: Building on our drug discovery pipeline to find and target orthogonal modalities of therapeutic resistance, we leveraged our bank of residual PDX tumors collected after 21-day exposure to SOC therapy, and now report that CDK1 and CDK2 are at the center of a stress response program that enables BRAF(V600E) CRC tumor cells to survive under therapeutic pressure. We used HT-KAM to interrogate the activity of 165 kinases and kinase families, and integrated these profiles using computational methods to model signaling pathways. Out of the reprogrammed kinomes of BRAFi + EGFRi resistant tumors, the CDK1/2 kinases and mechanisms of cell cycle checkpoint emerged as critical dependencies. We validated these findings using multiplex immuno-fluorescence in residual tumors, protein/gene expression profile of tissues and cell lines (e.g., upregulation of Cyclins and CDC25s), and cell viability assay using dinaciclib, a CDK1/2 inhibitor. Considering that COX2i has minimal toxicity, yet improved tumor growth inhibition when added to SOC, we evaluated whether jointly blocking inflammatory pathway (COX2) and cell cycle checkpoints (CDK1/2) could overcome resistance. We found that co-targeting CDK1/2 along with BRAFi + EGFRi ± COX2i is well-tolerated in mice and promotes significant, durable suppression of tumor growth in multiple PDX models, including tumor regression, over 9 weeks of treatment. Conclusion: When tumors progress on SOC BRAFi + EGFRi, a therapeutic window remains open to switch to a CDK1/2i-containing regimen and restore cancer control. Citation Format: Jean-Philippe Coppe, Denise P. Muñoz, Chloe E. Atreya, Yeonjoo Hwang, Mehdi Bouhaddou, Louise E. Heinrich, Mohammad Naser, Ons Zakraoui, Roxana Pirker, Rupa Guha, Christina Moelders, Alessandro Scapozza, Cecilia Schwarzer, Layla Phillips, Changjun Wang, Laura van 't Veer, Veronica Steri, Scott R. VandenBerg. Targeting CDK1/2-driven mechanisms of resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal cancer restores therapeutic response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4735.

Abstract 5486: Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer

Abstract 1218: CDK9 inhibitors modulate the transcriptional landscape of colorectal cancer to suppress MAPK signaling and synergizes with BRAF inhibitors to treat BRAF-mutant colorectal cancer

Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6

Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

Abstract 5499: Synergistic Effects of the Combination of ERK1/2 with EGFR, KRASG12C, CDK4/6, and PD-L1 Inhibition for Cancer Treatment

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer

Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

The interaction of radiotherapy and dual inhibition of BET and HAT/p300 in colorectal cancer.

Abstract 4735: Targeting CDK1/2-driven mechanisms of resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal cancer restores therapeutic response

Combine MEK Inhibition with PI3K/mTOR Inhibition Exert Inhibitory Tumor Growth Effect on KRAS and PIK3CA Mutation CRC Xenografts Due to Reduced Expression of VEGF and Matrix Metallopeptidase-9

Abstract 3241: Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer

Abstract 2673: Combined inhibition of PI3K and HDAC1/2 as a novel treatment strategy for RAS/RAF wildtype colorectal cancer in a patient derived organoid model

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer

A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer

Abstract A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Abstract 1083: MEKi and SOS1i as a combination treatment option for KRAS mutant endometrial cancer

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death

Cnsc-25. Concurrent Immune Checkpoint Blockade Enhances The Survival Benefit Of Clinically Relevant Mapk Pathway Inhibitors In A T Cell-Dependent Manner